Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(11 sites)

China

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong

Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong

Hainan General Hospital, Haikou, Hainan

Henan Cancer Hospital, Zhengzhou, Henan

Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei

The First Affilated Hospital of Soochow University, Suzhou, Jiangsu

People's hospital of Jiangsu Province, Suzhou, Jiangsu

The First Affilated Hospital of Nanchang University, Nanchang, Jiangxi

Institute of blood transfusion of Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality

The First Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou, Zhejiang